RVX-208: Completed Phase IIb enrollment

Resverlogix said it completed enrollment in the double-blind, placebo-controlled, international Phase IIb ASSURE trial evaluating twice-daily 100 mg oral RVX-208 for 26 weeks in about 310 patients wi...